
|Articles|September 1, 2003
New Products & Services
Raritan, NJ-Ortho-McNeil Pharmaceutical has received FDA approval to market levofloxacin (Levaquin) for the treatment of chronic bacterial prostatitis caused by Escherichia coli, Enterococcus faecalis, or Staphylococcus epidermidis.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures
2
BOND-003: Cretostimogene yields durable 24-month responses in high-grade NMIBC
3
Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC
4
FDA grants 510(k) clearance to Vanquish Water Vapor System for intermediate-risk prostate cancer
5


















